[
    [
        {
            "time": "2021-10-22",
            "original_text": "康泰生物：公司目前预约第三季度报告的披露时间为2021年10月22日",
            "features": {
                "keywords": [
                    "第三季度报告",
                    "披露时间"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "康泰生物：公司目前预约第三季度报告的披露时间为2021年10月22日",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "2021-unknown",
            "original_text": "康泰生物：公司已积极安排13价肺炎球菌多糖结合疫苗的生产、销售工作",
            "features": {
                "keywords": [
                    "13价肺炎球菌多糖结合疫苗",
                    "生产",
                    "销售"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "康泰生物：公司已积极安排13价肺炎球菌多糖结合疫苗的生产、销售工作",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-06-unknown",
            "original_text": "康泰生物：新冠灭活疫苗III期临床试验在今年6月已开始接种首针",
            "features": {
                "keywords": [
                    "新冠灭活疫苗",
                    "III期临床试验",
                    "接种首针"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "康泰生物：新冠灭活疫苗III期临床试验在今年6月已开始接种首针",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2021-unknown",
            "original_text": "康泰生物：公司生产经营正常，生产基地所在区域不限电措施影响",
            "features": {
                "keywords": [
                    "生产经营正常",
                    "不限电措施"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "康泰生物：公司生产经营正常，生产基地所在区域不限电措施影响",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-unknown",
            "original_text": "康泰生物：公司民海生物新型疫苗国际化产业基地建设项目（一期）尚处于建设期",
            "features": {
                "keywords": [
                    "民海生物",
                    "新型疫苗",
                    "国际化产业基地",
                    "建设期"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "康泰生物：公司民海生物新型疫苗国际化产业基地建设项目（一期）尚处于建设期",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 4,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-unknown",
            "original_text": "康泰生物：公司研发人员占公司总人数的比例在20%左右",
            "features": {
                "keywords": [
                    "研发人员",
                    "比例",
                    "20%"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "康泰生物：公司研发人员占公司总人数的比例在20%左右",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 4,
                "Headline_Structure": 4,
                "Source_Recency": 4
            }
        }
    ]
]